Pyxis Oncology Inc
pyxisoncology.comWhat Do They Do?
Develops an investigational antibody-drug conjugate for people with solid tumors, with an immediate focus on head and neck squamous cell cancer.
10-K for FY2025, filed Mar 23, 2026Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients…View ↗
Our lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational novel antibody-drug conjugate (ADC) that…View ↗
MICVO is currently being studied as monotherapy in recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in…View ↗
How Do They Make Money?
Revenue included proceeds from selling royalty rights, milestone payments tied to a partner’s performance, and royalties tied to product sales under collaboration or out-license arrangements.
-
10-K for FY2025, filed Mar 23, 2026
FY2025 revenue by product or service ↗
$13.9M
-
10-K for FY2025, filed Mar 23, 2026
$13.9M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Royalty Revenues
Licensed
|
0.0% |
Royalty Revenues, FY2025
$0 Sources
|
Licensed |
|
Sale of Royalty Rights
|
80% |
Sale of Royalty Rights, FY2025
$11M Sources
|
|
|
Milestone Revenue
Licensed
10-K for FY2025, filed Mar 23, 2026 |
20% |
Milestone Revenue, FY2025
$2.8M Sources
|
Licensed |
Do Revenues Turn Into Profits?
No. It lost $79.6M in FY2025.
10-K for FY2025, filed Mar 23, 2026
−$84.4MView ↗
10-K for FY2025, filed Mar 23, 2026
−$79.6MView ↗
10-K for FY2025, filed Mar 23, 2026
−$63.5MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$25.3MView ↗
- ▲ +38% (Loss)
- vs −$18.4M in Q2 FY2025
-
Sep 3, 2026
Thomas Civik was appointed CEO and board chair
John Flavin transitioned to lead independent director.
Sources
8-K, filed Sep 8, 2026
On September 4, 2026, the Board of Directors (the “Board”) of Pyxis Oncology, Inc. (the “Company”) appointed Thomas Civik, the Company’s…View ↗
A narrower drug-development focus
The older report described candidates across antibody-drug conjugates, immunotherapy and antibody discovery; the latest centers on MICVO, studied alone and with pembrolizumab, with head and neck cancer as its immediate focus.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 23, 2026
Who Do They Compete With?
Competes with AbbVie, Abcure, ADC Therapeutics, Alligator Bioscience, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Daiichi Sankyo, Eucure Biopharma, Genentech, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Lyvgen Biopharma, Nextcure, Pfizer, Philogen, Merck Sharpe & Dohme, Corbus Pharmaceuticals, and Rakuten Medical
10-K for FY2025, filed Mar 23, 2026If our product candidate is licensed, it will compete with a range of therapeutic treatments that are either in development or currently…View ↗
Loading...
